Trial Profile
A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab +/- Lenalidomide
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Dinutuximab (Primary) ; Lenalidomide (Primary) ; Natural killer cell therapy (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- Acronyms NANT
- 12 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 12 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 30 Jan 2023 Planned End Date changed from 1 Aug 2023 to 1 Sep 2023.